Vaccines & Immunotherapy

mRNA and other vaccine platforms have moved beyond COVID into cancer, RSV, HIV and rare disease. The session covers personalised cancer mRNA vaccines (BNT122, mRNA-4157 in melanoma and NSCLC), immune checkpoint inhibitor combinations and resistance mechanisms, CAR-T expanding into solid tumours (DLL3 tarlatamab as proof of concept), universal flu vaccine candidates, self-amplifying RNA platforms, and adjuvant innovation. Discussion addresses vaccine hesitancy and uptake, equity in vaccine access globally, the Henrietta Lacks foundation framework for cell-line consent, IL-2 superagonists and other cytokine modulators, and the regulatory landscape for personalised cancer vaccines.